Почетна › Параганглиом › Merilend
Kliničke studije za Параганглиом u državi Merilend
7 studija za Параганглиом traži učesnike na lokacijama u državi Merilend.
Zvanični tekst studije (na engleskom)
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108), Baltimore
- National Institutes of Health ( Site 0125), Bethesda
Тражи се учесникФаза 2
Узраст 12 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT04924075A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникФаза 1
Узраст од 18 до 120 · Оба пола · Ажурирано 9. 11. 2026. · NCT0604151618F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникФаза 2
Узраст од 18 до 120 · Оба пола · Ажурирано 29. 10. 2026. · NCT06503146Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникФаза 2
Узраст од 18 до 100 · Оба пола · Ажурирано 26. 10. 2026. · NCT03206060Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникФаза 1/2
Узраст од 18 до 120 · Оба пола · Ажурирано 16. 10. 2026. · NCT06427798Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- Johns Hopkins, Baltimore
Тражи се учесникФаза 1/2
Узраст од 18 до 90 · Оба пола · Ажурирано 13. 10. 2026. · NCT05636618[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникФаза 1
Узраст од 18 до 120 · Оба пола · Ажурирано 6. 10. 2026. · NCT06479811Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.